Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Mar 10:10:1101-10.
doi: 10.2147/DDDT.S103423. eCollection 2016.

Formulation and clinical evaluation of silymarin pluronic-lecithin organogels for treatment of atopic dermatitis

Affiliations

Formulation and clinical evaluation of silymarin pluronic-lecithin organogels for treatment of atopic dermatitis

Fatma M Mady et al. Drug Des Devel Ther. .

Abstract

Silymarin is a naturally occurring flavonoid drug; evidence from recent research has highlighted its use as a potential treatment for atopic dermatitis (AD). Both poor water solubility and drug permeability have hindered the percutaneous absorption of silymarin. Formulation of silymarin into pluronic-lecithin organogel (PLO) basis for topical skin delivery is the main aim of this work. Six different PLO formulations were prepared containing various pluronic to lecithin ratios using two cosolvent systems of ethyl alcohol and dimethyl sulfoxide. Formulation 2 (20% pluronic and 3% lecithin) was found to be the optimal base for topical delivery of silymarin as it showed optimum pH, viscosity, drug content, and satisfactory in vitro silymarin permeation. The silymarin PLO formulation significantly relieved inflammatory symptoms of AD such as redness, swelling, and inflammation. These findings warrant the ability for application of these novel silymarin PLO formulations as a novel treatment for AD.

Keywords: atopic dermatitis; pluronic lecithin organogel; silymarin; skin penetration.

PubMed Disclaimer

Figures

Figure 1
Figure 1
FTIR spectroscopy. Notes: Silymarin (A), PLO gel free base (B), drug loaded PLO gel (C). Abbreviations: FTIR, Fourier transform infrared spectroscopy; PLO, pluronic-lecithin organogel.
Figure 2
Figure 2
Rheology behaviors of different PLO gels loaded with silymarin. Notes: F2 to F6: using 30% ethyl alcohol as a solvent; F2*: using 3% DMSO as a solvent. Abbreviations: PLO, pluronic-lecithin organogel; DMSO, dimethyl sulfoxide.
Figure 3
Figure 3
In vitro release of silymarin from different formulations of PLO gels. Notes: F2 to F6: using 30% ethyl alcohol as a solvent; F2*: using 3% DMSO as a solvent. Abbreviations: PLO, pluronic-lecithin organogel; hr, hours; DMSO, dimethyl sulfoxide.
Figure 4
Figure 4
Ex vivo permeability release (XF2, XF2*) compared with the in vitro release (F2, F2*) of silymarin from PLO gels. Note: F2, F2*, XF2, and XF2*: using 30% ethyl alcohol as a solvent. Abbreviations: PLO, pluronic-lecithin organogel; hr, hours.
Figure 5
Figure 5
Photographs of different AD patients before and after treatment with silymarin loaded PLO gels. 0
Figure 6
Figure 6
Comparison between control side and treated side with regards to itching.
Figure 7
Figure 7
Patient’s skin histology. Notes: Before (A) and after (B) treatment with silymarin loaded PLO gels. Magnification= 100×; Scale bar= 200 μm. Abbreviation: PLO, pluronic-lecithin organogel.

Similar articles

Cited by

References

    1. Darsow U, Raap U, Ständer SR. In: Itch: Mechanisms and Treatment. Carstens E, Akiyama T, editors. Boca Raton: CRC Press; 2014. pp. 832–836.
    1. Ring J, Przybilla B, Ruzicka T. Handbook of atopic eczema. 2nd ed. New York: Springer-Verlag Berlin Heidelberg; 2006.
    1. Friedmman PS, Holden CA. Atopic dermatitis. In: Burns T, Breathnach S, Cox N, Griffiths C, editors. Rook’s Textbook of Dermatology. 7th ed. Oxford, England: Blackwell Sciences; 2008. pp. 755–786.
    1. Charman C. Clinical evidence: atopic eczema. BMJ. 1999;318(7198):1600–1604. - PMC - PubMed
    1. Sudilovsky A, Muir JG, Bocobo FC. A comparison of single and multiple applications of halcinonide cream. Int J Dermatol. 1981;20(9):609–613. - PubMed